Holen Sie sich die Stockscreener-App
1.35
1.46%
-0.02
Handel nachbörslich:
1.40
0.05
+3.70%
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds - MSN
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Trading Up 6.3% – Still a Buy? - Defense World
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Clearmind Medicine Announces Shareholders Meeting Results - The Manila Times
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Clearmind Medicine files European patent for binge behavior therapy By Investing.com - Investing.com Nigeria
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Clearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
Clearmind Medicine files European patent for binge behavior therapy - Investing.com
Lexitas Elevates Nishat Mehta to CEO, Prepares to Launch AI-Assisted Solutions for the Legal Profession Throughout 2025 - The Manila Times
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - The Manila Times
Clearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property Office - GlobeNewswire Inc.
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
Clearmind Medicine to move forward with MEAI-based alcohol substitute - Yahoo Finance
Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute - EIN News
Clearmind Medicine Partners with Dr Glitter to Develop Crystal-Based Alcohol Alternative - StockTitan
Clearmind Medicine receives IRB approval for Phase I/IIa clinical trial of CMND-100 - MSN
Clearmind Medicine advances in AUD treatment trial By Investing.com - Investing.com South Africa
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
Clearmind Medicine Inc. Receives IRB Approval for its FDA-Regulated Clinical Trial - Marketscreener.com
SciSparc Ltd. Announces Finalize an Exclusive Patent License Agreement with Polyrizon Ltd - Marketscreener.com
Clearmind Medicine Inc. Announces Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Marketscreener.com
Scisparc Ltd. and Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - Marketscreener.com
SciSparc Ltd. Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss - Marketscreener.com
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Why Is Penny Stock Clearmind Gaining Today? - Benzinga
Regulatory Approval Sends Clearmind Medicine (CMND) Soaring Pre-Market - Stocks Telegraph
Clearmind Medicine Shares Double on Trial Approval - MarketWatch
Clearmind Medicine advances in AUD treatment trial - Investing.com
Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical Trial - The Manila Times
Clearmind Medicine (NASDAQ:CMND) Shares Up 3.5% – Time to Buy? - Defense World
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ Format - The Manila Times
Clearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI-Based Alcohol Substitute in ActivCrystal? Format - Marketscreener.com
Clearmind Medicine Partners to Create Revolutionary Crystal-Based Alcohol Alternative - StockTitan
Rail Vision unveils new SaaS platform for rail safety By Investing.com - Investing.com South Africa
Rail Vision unveils new SaaS platform for rail safety - Investing.com
Premium Access Slides: Current Tailwind % Scores and Relative Strength Rank & Trend Reports in a Google Slideshow? - substack.com
Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World
Bright Minds stock cools amid psychedelic volatility (DRUG:NASDAQ) - Seeking Alpha
Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News
Clearmind advances trial for alcohol use disorder therapy - Investing.com
Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia
Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register
Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Examining CMND’s book value per share for the latest quarter - US Post News
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com
Rail Vision secures $20 million equity deal with Yorkville - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):